达沙替尼联合紫杉醇和卡铂治疗晚期或复发性子宫内膜癌的初步临床与转化研究
结果显示客观缓解率为45%(95%CI:17%-77%),中位无进展生存期10.5个月,中位总生存期30.4个月。Caveolin-1表达联合CRAF/BRAF异二聚化与达沙替尼耐药相关,三药方案显示出一定临床活性且毒性可接受。
要点
- 达沙替尼联合紫杉醇和卡铂在晚期或复发性子宫内膜癌中客观缓解率45%。
- 中位无进展生存期10.5个月,中位总生存期30.4个月。
- Caveolin-1表达联合CRAF/BRAF异二聚化与达沙替尼耐药相关。
核心结论
- Caveolin-1表达联合CRAF/BRAF异二聚化与达沙替尼靶向EphA2的耐药相关。
- 三药联合方案在子宫内膜癌中显示出值得关注的临床活性,毒性可接受。
- 达沙替尼预处理可能加重联合治疗的毒性。
研究设计与样本
- 给予达沙替尼150 mg口服每日一次共14天,随后紫杉醇、卡铂联合达沙替尼每日一次共6个周期(21天为一周期)。
- 17例可评估毒性,11例可评估反应;比较治疗前后活检组织中EphA2信号下游效应物。
主要发现
- 反向相位蛋白阵列和邻近连接 assay 显示CRAF/BRAF二聚化、caveolin-1水平及Notch通路信号可预测达沙替尼的应答与耐药。
- 总体客观缓解率为45%(95% CI:17%-77%)。
- 中位无进展生存期为10.5个月,中位总生存期为30.4个月。
- 最常见的3或4级不良事件为中性粒细胞减少(76%)、血小板减少(53%)、贫血(53%)和乏力(12%)。
临床怎么用
- 达沙替尼联合紫杉醇和卡铂可作为晚期或复发性子宫内膜癌的潜在治疗选择,但需注意骨髓抑制等毒性。
- caveolin-1表达联合CRAF/BRAF异二聚化可能作为达沙替尼耐药的预测标志物。
局限性
- 达沙替尼预处理可能加重联合治疗毒性,需谨慎设计给药顺序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the effect of dasatinib therapy on EphA2 signaling in cancers of women with measurable (biopsy amenable) advanced-stage, chemo-naïve primary or recurrent endometrial cancer. Preliminary efficacy was also assessed. PATIENTS AND METHODS: We performed a pilot study of single-agent dasatinib lead-in, followed by triplet dasatinib, paclitaxel, and carboplatin. We measured the downstream effectors of EphA2 signaling in pre- and post-dasatinib treatment biopsy tissue samples; we also determined the severity of adverse events and patients' progression-free survival and overall survival durations. RESULTS: Eighteen patients were recruited and given dasatinib (150 mg orally daily for 14 days), followed by paclitaxel, carboplatin and dasatinib (daily) for six cycles (21-day cycles). Seventeen patients were evaluable for toxicity and 11 patients for response. A reverse phase protein array and proximity ligation assay revealed that CRAF/BRAF dimerization, caveolin-1 level, and Notch pathway signaling were predictive of response and resistance to dasatinib. Overall, the objective response rate was 45% (95% CI: 17%-77%), with median progression-free survival duration of 10.5 months and median overall survival duration of 30.4 months. The most common grade 3 or 4 adverse events were neutropenia (76%), thrombocytopenia (53%), anemia (53%), and fatigue (12%). CONCLUSIONS: Caveolin-1 expression, in combination with CRAF/BRAF heterodimerization, is associated with resistance to EphA2 targeting by dasatinib. The triplet combination showed interesting clinical activity in endometrial cancer with acceptable toxicity. Pretreatment with dasatinib may accentuate combination therapy toxicity.
引用
- Coleman RL, Hu W, Soliman P, et al. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021. PMID: 33551196. doi:10.1016/j.ygyno.2021.01.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。